To Study Safety, Tolerability and Pharmacokinetics of AZD1305 in Healthy Male Japanese Subjects
Launched by ASTRAZENECA · Aug 18, 2008
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • A body mass index (BMI=weight/height2) of 19 to 27 kg/m2
- • Japanese males
- Exclusion Criteria:
- • ECG findings outside normal reference ranges.
- • Potassium outside normal reference ranges.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fukuoka, , Japan
Patients applied
Trial Officials
Helen Lunde, MD
Study Director
AstraZeneca R&D, Mölndal, Sweden
Kyoko Matsuguma, MD
Principal Investigator
Kyushu Clinical Pharmacology Research Clinic, Fukuoka, Japan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials